Literature DB >> 18379450

Clinical results in the management of Frey's syndrome with injections of Botulinum toxin.

Pedro Martos Díaz1, Raquel Bances del Castillo, María Mancha de la Plata, Luis Naval Gías, Concepción Martínez Nieto, Gui-Youn Cho Lee, Mario Muñoz Guerra.   

Abstract

INTRODUCTION: Frey's Syndrome is defined by facial hyperhidrosis in the preauricular region unleashed by gustatory stimulus and caused mainly by parotidectomy. Several treatment and prevention measures have been proposed, with no conclusive results. Recently, injections of Botulinum Toxin have been suggested, obtaining encouraging results. The objective is to describe our experience in treating Frey's Syndrome with this drug. MATERIALS AND
METHOD: Between 2004 and 2007, our team treated 10 patients suffering from Frey's Syndrome. All cases were caused by parotid resection. In 60%of cases a complete elevation of the SMAS (superficial musculoaponeurotic system) was carried out. In the remaining cases, such elevation was either not made or the SMAS was severely damaged. All patients were treated with intradermic injections of Botulinum Toxin. Recorded data were: units administered, affected area, time lapse until improvement in the symptoms, and the evolution after one, six and twelve months after the injection. Possible side effects were also recorded.
RESULTS: The average treated area per patient was 26 cm2. An average of 38 units of Botulinum Toxin per patient was injected. Average time lapse until improvement was 5.5 days. Five patients were injected with a second dose after an average of 18 months from the first injection. On this occasion, the area affected was considerably smaller than that presented before the first injection. The most frequently reported side effect was dry mouth.
CONCLUSION: Our team considers that treating Frey's Syndrome with Botulinum Toxin is effective. The effects of the treatment are long-lasting and side effects are minimal and temporary. A second injection is needed after 15 to 18 months of the first, although the affected area is usually smaller.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379450

Source DB:  PubMed          Journal:  Med Oral Patol Oral Cir Bucal        ISSN: 1698-4447


  6 in total

1.  The Efficiacy of Sternocleidomastoid Muscle Flap on Frey's Syndrome via a Novel Test: Galvanic Skin Response.

Authors:  Ugur Demirci; Oguz Basut; Behzat Noyan; Uygar Levent Demir; O Afsin Ozmen; Fikret Kasapoglu; H Hakan Coskun; Selcuk Onart
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-31

2.  Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles.

Authors:  Shang Xie; Kan Wang; Tao Xu; Xue-Sheng Guo; Xiao-Feng Shan; Zhi-Gang Cai
Journal:  Cancer Med       Date:  2015-08-26       Impact factor: 4.452

Review 3.  Botulinum toxin: The Midas touch.

Authors:  P S Shilpa; Rachna Kaul; Nishat Sultana; Suraksha Bhat
Journal:  J Nat Sci Biol Med       Date:  2014-01

Review 4.  Toxin yet not toxic: Botulinum toxin in dentistry.

Authors:  M S Archana
Journal:  Saudi Dent J       Date:  2015-12-21

5.  Use of botulinum toxin type A in Frey's syndrome.

Authors:  Gustavo Vieira Gualberto; Felipe Mauricio Soeiro Sampaio; Natália Augusta Brito Madureira
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

Review 6.  Botulinum Neurotoxins and Cancer-A Review of the Literature.

Authors:  Shivam Om Mittal; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2020-01-05       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.